Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C (NPC-1)

NCT03893071 is registered in ClinicalTrials.gov with Cyclo Therapeutics, Inc. as lead sponsor.

NCT NCT03893071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of the Long-Term Safety and Efficacy of Intravenous Trappsol® Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C (NPC-1)
Lead sponsor
Cyclo Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
May 23, 2019
Completion date
March 31, 2022
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

niemann-pick disease, type c1